Vasopressin Initiation Timing and In-Hospital Mortality in Septic Shock: An Observational Study of Large Public...

Area of Science:

• Critical Care Medicine
• Pharmacology
• Epidemiology

Background:

• Vasopressin (VP) is a key agent for hemodynamic support in septic shock, often used to reduce catecholamine requirements.
• The optimal timing and clinical conditions for initiating VP remain unclear, impacting patient outcomes.

Purpose of the Study:

• To investigate the association between norepinephrine-equivalent dose, lactate levels, and time to VP initiation with in-hospital mortality in septic shock patients.
• To identify critical thresholds for these variables that influence mortality risk.

Main Methods:

• Retrospective analysis of adult septic shock patients receiving continuous catecholamine infusions from the MIMIC-IV and eICU databases.
• Multivariable regression models were used to assess the impact of norepinephrine-equivalent dose, lactate concentration, and time from shock onset to VP initiation on in-hospital mortality.

Main Results:

• 1409 patients were included. Higher norepinephrine-equivalent doses (e.g., ≥28 µg/min and ≥72 µg/min) at VP initiation significantly increased mortality odds.
• Elevated lactate concentrations (16% increased odds per mmol/L) and longer duration from shock onset to VP initiation (3% increased odds per hour) were also associated with higher in-hospital mortality.

Conclusions:

• Initiating vasopressin earlier in the course of septic shock, particularly at lower norepinephrine-equivalent doses and with lower lactate levels, may be associated with reduced in-hospital mortality.
• These findings highlight the importance of timely and appropriate vasopressin administration in managing septic shock.